INVITATION
Mirati Therapeutics, Inc. - Advancing Tailored Therapies in NSCLC and KRASG12C-Driven Tumors
INVITATION
Gilead and Kite Oncology - CAR T-cell therapy: The next frontier in immuno-oncology
Mirati Therapeutics, Inc. - Advancing Tailored Therapies in NSCLC and KRASG12C-Driven Tumors
Gilead and Kite Oncology - CAR T-cell therapy: The next frontier in immuno-oncology